Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SCD | O00767 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL473008 | 0.98 | HRH1 (0.55) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL7888184 | 0.90 | HTR1A (0.58) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL1782071 | 0.90 | HTR1A (0.58) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL2819314 | 0.90 | HTR1A (0.58) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| Trifluoroacetic Acid SCHEMBL69823 | 0.90 | HRH1 (0.51) | HRH1SLC6A2HTR1ASLC6A3SCD | |
| Hydrochloric Acid SCHEMBL2947998 | 0.89 | HTR1A (0.57) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL31071563 | 0.84 | SLC6A2 (0.48) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL5365259 | 0.83 | HRH1 (0.57) | HRH1SLC6A2HTR1ASLC6A3HTR2C | |
| SCHEMBL1230447 | 0.83 | SLC6A2 (0.54) | SLC6A2HTR1ASLC6A3HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL3094545 | 0.82 | HRH1 (0.55) | HRH1SLC6A2HTR1ASLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| EP-4674416-A1 | PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION | NAGASAKI UNIVERSITY (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024181431-A1 | PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION | 国立大学法人 長崎大学 | 2024-09-06 | — | — | WO | disclosed |
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| CN-108456204-B | Benzothiazine derivative, and preparation method and application thereof | 四川大学 | 2023-05-26 | — | — | CN | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006130986-A1 | AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-4411904-A | Diphenylpropanamines, compositions thereof and use thereof | WARNER-LAMBERT COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4364954-A | NEUROLEPTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1982-12-21 | — | — | US | disclosed |
| US-4292321-A | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof | WARNER-LAMBERT COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | HRH1 1208/4885SLC6A2 1380/4885HTR1A 2372/4885 |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | HRH1 3298/4885SLC6A2 4708/4885HTR1A 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.